SCHEMBL21388735

SCHEMBL21388735

CC(C)c1cnc(N2CCCC2)c(=O)[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.37
JAK2 O60674 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
POLB P06746 2/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
KDM5B Q9UGL1 3/20 0.34
KDM4E B2RXH2 1/20 0.34
IP6K1 Q92551 1/20 0.33
HRH4 Q9H3N8 2/20 0.33
NPY5R Q15761 1/20 0.33
HTR3A P46098 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
MAT2A P31153 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24866843 0.98 KDM5A (0.39) KDM5AJAK2ALDH1A1MEN1KMT2A
SCHEMBL24866878 0.87 PDE9A (0.38)
SCHEMBL21399318 0.84 MEN1 (0.35) KDM5AJAK2ALDH1A1MEN1KMT2A
SCHEMBL21398890 0.82 HSD17B10 (0.31) ALDH1A1HSD17B10
SCHEMBL21399141 0.80
SCHEMBL23173104 0.80 PTPN11 (0.44)
SCHEMBL21399329 0.80 ENPP1 (0.32)
SCHEMBL24866594 0.79 AKT2 (0.34)
SCHEMBL24866463 0.79 CYP11B1 (0.39) MAPK1
SCHEMBL24866507 0.79 ENPP1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230010886-A1 SHP2 INHIBITORS AND USES THEREOF Suzhou Puhe BioPharma Co., Ltd. (CN) 2023-01-12 US disclosed
US-10561655-B2 SHP2 inhibitors and uses thereof SYNBLIA THERAPEUTICS, INC. (US) 2020-02-18 US disclosed
WO-2019182960-A1 SHP2 INHIBITORS AND USES THEREOF SYNBLIA THERAPEUTICS, INC. (US) 2019-09-26 WO disclosed
US-20190290649-A1 SHP2 INHIBITORS AND USES THEREOF Suzhou Puhe BioPharma Co., Ltd. (CN) 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230010886-A1 SHP2 INHIBITORS AND USES THEREOF PTPN1, PTPN7, PTPN18 KDM5A 2110/4885JAK2 49/4885ALDH1A1 3180/4885
US-20190290649-A1 SHP2 INHIBITORS AND USES THEREOF PTPN1, PTPN7, PTPN18 KDM5A 2110/4885JAK2 49/4885ALDH1A1 3180/4885
US-10561655-B2 SHP2 inhibitors and uses thereof PTPN1, PTPN7, PTPN18 KDM5A 2110/4885JAK2 49/4885ALDH1A1 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.